Prime Medicine Analyst Ratings
Prime Medicine Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2022 | 27.84% | JP Morgan | → $27 | Initiates Coverage On | → Overweight |
| 11/14/2022 | 18.37% | Jefferies | → $25 | Initiates Coverage On | → Buy |
| 11/14/2022 | 8.9% | Morgan Stanley | → $23 | Initiates Coverage On | → Equal-Weight |
| 11/14/2022 | 4.17% | Goldman Sachs | → $22 | Initiates Coverage On | → Neutral |
What is the target price for Prime Medicine (PRME)?
The latest price target for Prime Medicine (NASDAQ: PRME) was reported by JP Morgan on November 14, 2022. The analyst firm set a price target for $27.00 expecting PRME to rise to within 12 months (a possible 27.84% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Prime Medicine (PRME)?
The latest analyst rating for Prime Medicine (NASDAQ: PRME) was provided by JP Morgan, and Prime Medicine initiated their overweight rating.
When is the next analyst rating going to be posted or updated for Prime Medicine (PRME)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prime Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prime Medicine was filed on November 14, 2022 so you should expect the next rating to be made available sometime around November 14, 2023.
Is the Analyst Rating Prime Medicine (PRME) correct?
While ratings are subjective and will change, the latest Prime Medicine (PRME) rating was a initiated with a price target of $0.00 to $27.00. The current price Prime Medicine (PRME) is trading at is $21.12, which is within the analyst's predicted range.
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2022 | 27.84% | JP Morgan | → $27 | Initiates Coverage On | → Overweight |
| 11/14/2022 | 18.37% | Jefferies | → $25 | Initiates Coverage On | → Buy |
| 11/14/2022 | 8.9% | Morgan Stanley | → $23 | Initiates Coverage On | → Equal-Weight |
| 11/14/2022 | 4.17% | Goldman Sachs | → $22 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/14/2022 | 27.84% | 摩根大通 | → $27 | 開始承保 | →超重 |
| 11/14/2022 | 18.37% | 傑富瑞 | → $25 | 開始承保 | →購買 |
| 11/14/2022 | 8.9% | 摩根士丹利 | → $23 | 開始承保 | →等重 |
| 11/14/2022 | 4.17% | 高盛 | → $22 | 開始承保 | →中性 |
What is the target price for Prime Medicine (PRME)?
Prime Medicine(PRME)的目標價格是多少？
The latest price target for Prime Medicine (NASDAQ: PRME) was reported by JP Morgan on November 14, 2022. The analyst firm set a price target for $27.00 expecting PRME to rise to within 12 months (a possible 27.84% upside). 4 analyst firms have reported ratings in the last year.
優質醫藥(納斯達克代碼：PRME)的最新目標價是由摩根大通於2022年11月14日報道的。這家分析公司將目標價定為27美元，預計PRME將在12個月內上漲至27.84%(可能上漲27.84%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Prime Medicine (PRME)?
最新分析師對Prime Medicine(PRME)的評級是多少？
The latest analyst rating for Prime Medicine (NASDAQ: PRME) was provided by JP Morgan, and Prime Medicine initiated their overweight rating.
優質醫藥(納斯達克股票代碼：PRME)的最新分析師評級是由摩根大通提供的，優質醫藥啟動了他們的增持評級。
When is the next analyst rating going to be posted or updated for Prime Medicine (PRME)?
Prime Medicine(PRME)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prime Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prime Medicine was filed on November 14, 2022 so you should expect the next rating to be made available sometime around November 14, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Prime Medicine的高管和客户交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Prime Medicine的上一次評級是在2022年11月14日提交的，所以你應該預計下一次評級將在2023年11月14日左右提供。
Is the Analyst Rating Prime Medicine (PRME) correct?
分析師對Prime Medicine(PRME)的評級正確嗎？
While ratings are subjective and will change, the latest Prime Medicine (PRME) rating was a initiated with a price target of $0.00 to $27.00. The current price Prime Medicine (PRME) is trading at is $21.12, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Prime Medicine(PRME)評級是以0.00美元至27.00美元的目標價啟動的。Prime Medicine(PRME)目前的交易價格為21.12美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧